BioWorld Science - Articles

Other news to note for March 21, 2023

March 21, 2023

Additional early-stage research and drug discovery news in brief, from: Mymd Pharmaceuticals.

Cancer

Biomea Fusion discovers new FLT3 inhibitors for cancer

March 21, 2023

Biomea Fusion Inc. has described irreversible inhibitors of FLT3 (FLK2/STK1) reported to be useful for the treatment of cancer.

Neurology/Psychiatric

Hangzhou Healzen Therapeutics presents new KCNQ2/3 potassium channel activators

March 21, 2023

Hangzhou Healzen Therapeutics Co. Ltd. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, among others.

Neurology/Psychiatric

Artivila Therapeutics describes new SARM1 inhibitors

March 21, 2023

Artivila Therapeutics (Shenzhen) Co. Ltd. has identified NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of Alzheimer's and Parkinson's diseases, multiple sclerosis, amyotrophic lateral sclerosis and peripheral neuropathy.

Cancer

Fibrogen divulges new KDM5 inhibitors

March 21, 2023

Fibrogen Inc. has synthesized inhibitors of lysine-specific demethylase 5 (KDM5), particularly KDM5B (JARID1B), reported to be useful for the treatment of cancer, anxiety disorder, schizophrenia, viral infection, bipolar disorder, autism, Alzheimer's and Huntington's diseases, among others.

Cancer

CSPC Megalith Biopharmaceutical patents new antibody-drug conjugates for cancer

March 21, 2023

CSPC Megalith Biopharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a humanized monoclonal antibody targeting nectin-4 covalently linked to cytotoxic agents through a linker. They are reported to be useful for the treatment of cancer.

Immuno-oncology

Coimmune exercises option to license IL-18 armored CAR technology from MSK

March 21, 2023

Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.

Newborn baby feet and DNA base pair letters A, T, C and G.

Biomarkers

New pathogenic variant in NEB confirms diagnosis of nemaline myopathy 2

March 21, 2023

Researchers from the University of Utah applied RNASeq analysis for an undiagnosed case of a critically ill newborn with a complex phenotype, with the aim of providing better diagnosis and improving treatment outcomes.

Drug Design, Drug Delivery & Technologies

Charm Therapeutics and Bristol Myers Squibb establish drug discovery collaboration

March 21, 2023

Charm Therapeutics Ltd. has entered into a strategic discovery collaboration with Bristol Myers Squibb Co. for the identification and optimization of compounds against Bristol Myers Squibb's selected targets.

Musculoskeletal

Gilead exercises option to license oral IRAK-4 degrader under collaboration with Nurix

March 21, 2023

Gilead Sciences Inc. has exercised its option to exclusively license Nurix Therapeutics Inc.'s investigational targeted protein degrader molecule NX-0479, now designated GS-6791. This bivalent degrader is the first development candidate resulting from the companies' collaboration to discover, develop and commercialize up to five innovative targeted protein degradation therapies.